

Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma

Nina Ditsch, D. Mayr, M. Lenhard, C. Strauss, A. Vodermaier, J. Gallwas, D. Stoeckl, M. Graeser, T. Weissenbacher, K. Friese, Udo Jeschke

Angaben zur Veröffentlichung / Publication details:

Ditsch, Nina, D. Mayr, M. Lenhard, C. Strauss, A. Vodermaier, J. Gallwas, D. Stoeckl, et al. 2012. "Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma." *Oncology Letters* 4 (4): 665–71. <https://doi.org/10.3892/ol.2012.799>.

Nutzungsbedingungen / Terms of use:

licgercopyright

Dieses Dokument wird unter folgenden Bedingungen zur Verfügung gestellt: / This document is made available under these conditions:

Deutsches Urheberrecht

Weitere Informationen finden Sie unter: / For more information see:

<https://www.uni-augsburg.de/de/organisation/bibliothek/publizieren-zitieren-archivieren/publiz/>



Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma

NINA DITSCH¹, DORIS MAYR², MIRIAM LENHARD¹, CAROLIN STRAUSS³, ANDREA VODERMAIER^{1,4}, JULIA GALLWAS¹, DORIS STOECKL¹, MONIKA GRAESER⁵, TOBIAS WEISSENBACHER⁶, KLAUS FRIESE^{1,6} and UDO JESCHKE⁶

¹Department of Obstetrics and Gynaecology, Grosshadern, Ludwig-Maximilians-University, Munich, D-81377;

²Department of Pathology, Ludwig-Maximilians-University, Munich, D-80337; ³Department of Obstetrics and Gynaecology, Christian-Albrechts-University of Kiel, Kiel, D-24105, Germany; ⁴Department of Psychology, University of British Columbia,

Vancouver, BC, Canada; ⁵Department of Obstetrics and Gynaecology, University of Cologne, Cologne, D-50931;

⁶Department of Obstetrics and Gynaecology, Maistrasse, Ludwig-Maximilians-University, Munich, D-80337, Germany

Received March 20, 2012; Accepted June 28, 2012

DOI: 10.3892/ol.2012.799

Abstract. Non-steroidal nuclear receptors play a major role in breast cancer development. A correlation among, and possible prognostic function of, the members of the nuclear receptor superfamily has been discussed controversially over the years. Hence, we conducted a quantification of the different expression levels of the thyroid receptor (TR), retinoid X receptor (RXR), peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) in malignant breast tumour tissue samples. Patients diagnosed and treated for breast cancer between 1990 and 2000 were included. Receptor expression was detected by immunohistochemical staining. Correlation analyses for the expression of the receptors were performed for the clinical and histopathological data. The paraffin-embedded tissue from 82 breast cancer patients was available. The different steroid receptors showed varying results when correlated with known histopathological markers. TR α 2 demonstrated the most significant correlations with steroid hormone receptors. Significant correlations between the major isoforms of TR, and between RXR, PPAR and VDR, were demonstrated in the patient sample. The immunohistochemical association of these receptors may provide the first proof of an interaction on the molecular level. This assumption awaits confirmation in studies with larger cohorts.

Introduction

Although the involvement of the oestrogen receptor (ER) and progesterone receptor (PR) in breast cancer development and growth is well-established, little is known about the relevance and correlation of steroid hormone receptors with other members of the related non-steroidal nuclear receptor family. The latter is divided into two subfamilies (1), the first including the oestrogen, androgen, progesterone and mineralocorticoid receptors and the second including the thyroid receptor (TR), vitamin D receptor (VDR), retinoic acid receptor (RAR), peroxisome proliferator-activated receptor (PPAR) and retinoid X receptor (RXR). The second group of receptors is able to form heterodimers with each other, function through appropriate ligands (2) and interact at the genetic level (3).

The immunohistochemical expression of these receptors in breast cancer cells is known (4) and their expression levels are higher than in normal breast tissue or benign breast lesions (5-8).

The hormone dependency of the mammary gland and the similarity of TR and ER/PR have led to the hypothesis that TR may be a prognostic marker in breast cancer patients (9). The ER has two isoforms (α and β), which are differentiated by their molecular construction yet identical in their basic effect (10). In this study, which focuses on ER detected at the time of first diagnosis of breast cancer, ER isoform α expression was measured since this is the main isoform for which the most authentic histopathological data have been shown in previous studies (11). PR was also detected at the time of the first breast cancer diagnosis.

In the case of the TRs, immunohistochemical staining of the best known isoforms was conducted. The three main isoforms are TR α 1, TR α 2 and TR β 1 (12), which show high homology in amino acid composition.

Synthetic ligands of RXR have been reported to induce arrest of growth and differentiation in breast cancer cells

Correspondence to: Professor Udo Jeschke, Department of Obstetrics and Gynaecology, Ludwig-Maximilians-University, 11 Maistrasse, Munich, Bavaria, D-80337, Germany
E-mail: udo.jeschke@med.uni-muenchen.de

Key words: thyroid receptor, retinoid X receptor, peroxisome proliferator-activated receptor, vitamin D receptor, breast cancer

Table I. Antibodies and working concentrations.

Antibody	Species isotype	Working dilution	Source
TR α 1/2	Polyclonal rabbit IgG	1:200	Abcam, Cambridge, MA, USA
TR α 1	Polyclonal rabbit IgG	1:1000	AbD Serotec Oxford, UK
TR α 2	Monoclonal rabbit IgG1	1:200	AbD Serotec, Oxford, UK
TR β 1/2	Polyclonal rabbit IgG	1:200	Zytomed, Berlin, Germany
TR β 1	Polyclonal rabbit IgG	1:200	Millipore, Schwalbach, Germany
TR β 2	Polyclonal rabbit IgG	1:100	Millipore, Schwalbach, Germany
RXR α	Mouse monoclonal IgG	1:150	Perseus Proteomics Inc., Tokyo, Japan
PPAR γ	Rabbit polyclonal IgG	1:1000	Abcam, Cambridge, MA, USA
VDR	Mouse monoclonal IgG2a	1:100	AbD Serotec, Oxford, UK

TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; VDR, vitamin D receptor.

in vitro and in animal models (13,14). Ligand activation of RXR and PPAR induces antitumour effects in breast cancer cells (15). For RXR, three isoforms exist (α , β and γ). The best data on their detection in malignant breast tumours are available for RXR α (8). For PPAR, most studies refer to the γ isoform (13,16).

VDR is expressed in epithelial, stromal and immune cells of the normal mammary gland and is dynamically regulated in the epithelial compartment during hormonal changes (17). Furthermore, the receptor exists in malignant dividing cell types which respond to 1,25 vitamin D3 (18).

The present study is an evaluation of the potential correlations among different steroid hormone receptors following their immunohistochemical detection.

Materials and methods

Patients and ethics. Patients with an initial diagnosis of anamnestic sporadic breast cancer who received treatment in the Department of Obstetrics and Gynaecology of the Ludwig-Maximilians-University (Munich, Germany) and whose tissue samples were obtained at the surgery in our institution between 1990 and 2000 were included. Patients were stratified into groups according to lymph node involvement, grading and histopathological type, as described previously (19).

Ethical approval was obtained from the local ethics committee at the University of Munich (Project No. 048-08). The participants provided written informed consent. The study was carried out according to the guidelines of the 1975 Declaration of Helsinki. All samples and clinical information were used anonymously.

TNM classification was conducted according to the WHO criteria (20). The histological grading classification proposed by Bloom and Richardson was determined according to a modification of the Elston and Ellis grading system (21). Further clinical and histopathological parameters collected included age, year of breast cancer diagnosis, tumour size, histopathological type, axillary node involvement, histological grading and oestrogen/progesterone receptor status. At the time of the

tissue extraction, Her-2/neu was not regularly investigated in Germany. As far as possible, it has now been determined for the existing slides. Values of 0 and 1 were considered to be negative, values of 3+ were classified as positive and in cases of 2+, a fluorescence *in situ* hybridisation (FISH) assay was performed.

Histological diagnostic evaluation and staging were performed by two experienced gynecologic pathologists.

Clinical data on the patients' diseases were available from patients' charts, aftercare files and tumour registry database information.

Immunohistochemistry. Immunohistochemistry was performed using a combination of pressure cooker heating and the standard streptavidin-biotin-peroxidase complex with the use of the mouse/rabbit-IgG-Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA). The antibodies used for staining are listed in Table I.

Briefly, paraffin-fixed tissue sections were dewaxed with xylol for 15 min and then rehydrated in descending concentrations of alcohol (100, 75 and 50%). Endogenous peroxidase activity was quenched by dipping the slides into 3% hydrogen peroxide (Merck, Darmstadt, Germany) in methanol for 20 min. For epitope retrieval, the sections were then incubated in a pressure cooker using sodium citrate buffer (pH 6.0) containing 0.1 M citric acid and 0.1 M sodium citrate in distilled water for 10 min. After cooling, the slides were washed in phosphate-buffered saline (PBS) twice. Non-specific binding of the primary antibodies was blocked by incubating the sections with diluted normal serum (10 ml PBS containing 150 μ l horse/goat serum and 50 μ l secondary antibody; Vector Laboratories) for 20 min at room temperature. Sections were incubated in diluted biotinylated secondary antibody (10 ml PBS containing 150 μ l horse/goat serum and some secondary antibody; Vector Laboratories) for 30 min and the avidin-biotin peroxidase complex (diluted in 10 ml PBS; Vector Laboratories) for 30 min. Visualisation was performed using the substrate and the chromogen 3,3'-diaminobenzidine (DAB; Dako, Glostrup, Denmark). Sections were counterstained with Mayer's acidic haematoxylin, dehydrated in an ascending

Table II. Baseline characteristics of participants.

Factor	n	%
Tumour size	82	100
pT1a	1	1
pT1b	15	18
pT1c	44	54
pT2	17	21
pT3	-	-
pT4	5	6
LNI	82	100
Yes	38	46
No	44	54
Grading	82	100
1	9	11
2	40	49
3	33	40
TR	82	100
$\alpha 1/2$	78	95
$\alpha 1$	78	95
$\alpha 2$	79	96
$\beta 1/2$	77	94
$\beta 1$	79	96
$\beta 2$	76	93
RXR α	78	95
PPAR γ	78	95
VDR	75	91

LNI, lymph node involvement; TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; VDR, vitamin D receptor.

series of alcohol concentrations and then covered. The determination of the different receptors is shown in Fig. 1A-D. Negative and positive controls (placental tissue) were used to assess the specificity of the immunoreactions. For negative controls (coloured blue), isotype-matched control antibodies of the same species (Dako, Hamburg, Germany) were applied to the breast cancer tissue. The control tissue showed neither nuclear nor cytoplasmic staining. Negative controls and unstained cells were blue (Fig. 1E). Positive cells were brown (Fig. 1F).

Slides were evaluated and digitalised with a Zeiss photomicroscope (AxioPhot; AxioCam, Zeiss, Jena, Germany). The immunoreactive score (IRS) was assigned according to Remmele and Stegner (22). The intensity and distribution patterns of specific immunohistochemical staining were evaluated using the semi-quantitative assay (23,24). The IRS score was calculated by multiplying the optical staining intensity (graded as 0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining) with the percentage of positively stained cells (0, no staining; 1, <10% of cells stained; 2, 11-50% of cells stained; 3, 51-80% of cells stained; 4, >81% of cells stained). Microscopic analysis was performed by two independent observers.




Figure 1. Immunohistochemical staining of (A) TR, (B) RXR, (C) PPAR and (D) VDR in human breast cancer tissue. The images show immunoreactions following incubation of tumour cells with the primary antibody (x10 and x25 lens). (E and F) Placental tissue serves as negative and positive controls for the receptors (here RXR). (E) For negative controls (blue), the isotypes matching the control antibodies of the same species were used. (F) Positive control shows TR staining of villous trophoblast cells. TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; VDR, vitamin D receptor.

Statistical analysis. Statistical analysis was performed using SPSS version 19.0 (PASW Statistics; SPSS Inc., IBM, Chicago, IL, USA). Correlation analysis of the receptor expression was performed using the non-parametric Mann-Whitney U test and the non-parametric Spearman's rho. All statistical tests were two-sided and $P < 0.05$ was considered to indicate a statistically significant result.

Results

Patient characteristics. The paraffin-embedded tissues of 82 patients were available for analyses. The age at primary diagnosis ranged from 54-95 years. All patients had received an initial diagnosis of breast cancer and had an invasive ductal histopathological type. Patient characteristics are detailed in Table II.

The detection of TR, RXR and PPAR expression was limited to the nuclei. However, VDR expression was also found in the cytoplasm of the tumours (Fig. 1A-D). Positive immunohistochemical results (Table III) and correlations with known histopathological markers were identified (Table IV).

The results of the single TR $\alpha 1/2$ antibodies with a median IRS of 4 (range, 0-12) differed from the combined antibody TR $\alpha 1/2$. For TR $\alpha 1/2$, the IRS median was 0 (range, 0-6).

Table III. Immunohistochemical staining results of all receptors.

Antigen	IRS negative (0-1) n (%)	IRS positive (2-12) n (%)
TR		
α1	23 (29)	55 (71)
α2	25 (32)	54 (78)
α1/2	59 (76)	19 (24)
β1	36 (46)	43 (54)
β2	16 (21)	60 (79)
β1/2	44 (57)	33 (43)
RXRα	11 (14)	74 (86)
PPARγ	33 (42)	45 (58)
VDR	6 (8)	89 (92)

IRS, immunoreactive score; TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; VDR, vitamin D receptor.

As for TRα1/2, the median IRS values of the individual TRβ1 and TRβ2 antibodies were higher with values of 2 and 3, respectively (range, 0-12). The TRβ1/2 results were comparable to those for TRα1/2 with a median IRS of 1 (range, 0-9).

For RXR, the median IRS value was 4 (range, 0-8) and for PPAR it was 2 (range, 0-12). VDR showed the highest value with an IRS of 8 (range, 0-12).

Correlation analysis among the histopathological parameters. Tumour size, lymph node involvement and grading were significantly correlated with each other (data not shown). ER/PR had no significant associations with tumour size, lymph node involvement or grading.

Correlation analysis of steroid family members with histopathological findings

Tumour size. Tumour size was negatively correlated with TRα1 [correlation coefficient (cc)=-0.357, P=0.001], TRα2 (cc=-0.329, P=0.003), TRβ1 and TRβ2 expression (cc=-0.293, P=0.009; cc=-0.314, P=0.006). TRα2 levels were higher in pT1 tumours (median IRS, 6) compared with pT2-4 tumours (P=0.024; Fig. 2). RXR and PPAR were not associated with tumour size. In correlation analyses, VDR was negatively associated with tumour size (cc=-0.278, P=0.016).

Axillary lymph node involvement. Lymph node involvement was negatively correlated with TRα2 (cc=-0.487, P=0.002) and VDR (cc=-0.411, P<0.01). However, only PPARγ had a positive significant correlation with lymph node involvement (cc=0.318, P=0.005).

Differentiation grading. Differentiation grading was negatively correlated with TRα2 (cc=-0.542, P=0.009) and RXRγ (cc=-0.248, P=0.029). Positive correlations of grading were only observed with PPARγ (cc=0.236, P=0.038).

Furthermore, the correlation analysis of ER/PR expression (data shown in Table IV) showed positive results for TRα2 expression in the tumours (cc=0.248, P=0.028) and also for TRβ1 (cc=0.252, P=0.025). A negative correlation was found




Figure 2. Box plot analysis of TRα2 and tumour size. The box plots show a higher IRS of TRα2 in small malignant breast tumours. IRS, immunoreactive score; TR, thyroid receptor.

between TRβ1/2 expression and ER/PR expression (cc=-0.349, P=0.002). For RXR, PPAR and VDR, the correlation analysis showed no significant values for ER/PR expression.

Her-2/neu. As determined by retrospective analyses, most patients had a negative Her-2 status (60/82, 80%). In 7 patients it was not possible to determine Her-2 expression. No significant correlations were demonstrated with other clinicopathological parameters (Table IV).

Correlations among the members of the steroid hormone receptor family. The results of the correlations among the single functionally related steroid hormone receptors are listed in detail in Table V.

Thyroid receptors. For the combined TRα1/2, a correlation was demonstrated with TRα1, TRβ1, TRβ2 and RXR. TRα1 expression was correlated with TRα1/2, TRβ2 and RXR. TRα2 showed positive correlations with TRβ2, RXR and VDR. No correlations with other steroid factors were found for TRβ1/2. TRβ1 correlated positively with TRβ2, PPAR and VDR. TRβ2 showed positive correlations with almost all receptors (TRα1/2, TRα1, TRα2, TRβ1, PPAR and VDR).

RXR. RXRα was positively correlated with TRα1, TRα2 and TRα1/2.

PPAR. PPARγ showed two correlations, with TRβ1 and TRβ2.

VDR. For VDR, significant correlations were demonstrated with TRα2, TRβ1 and TRβ2.

Discussion

The present study demonstrated significant correlations between the known histopathological parameters, including tumour size, lymph node involvement, differentiation grade, ER, PR and other members of the nuclear receptor family. Furthermore, significant correlations among different steroid receptors (excluding the combined TRβ1/2) were shown. To the best of our knowledge, this is the first study to examine the coexpression and thus the immunohistochemical correlation between members of steroid receptors in a cohort of breast cancer patients.

Table IV. Correlations of antibodies with histopathological data.

Antigen	Tumour size (pT)	LNI	Differentiation grade	ER/PR	Her-2/neu
TR α 1/2	ns	ns	ns	ns	ns
TR α 1	cc=-0.357, P=0.001	ns	ns	ns	ns
TR α 2	cc=-0.329, P=0.003	cc=-0.487, P=0.002	cc=-0.542, P=0.009	cc=0.248, P=0.028	ns
TR β 1/2	ns	ns	ns	cc=-0.349, P=0.002	ns
TR β 1	cc=-0.293, P=0.009	ns	ns	cc=0.252, P=0.025	ns
TR β 2	cc=-0.314, P=0.006	ns	ns	ns	ns
RXR α	ns	ns	cc=-0.248, P=0.029	ns	ns
PPAR γ	ns	cc=0.318, P=0.005	cc=0.225, P=0.047	ns	ns
VDR	cc=-0.278, P=0.016	cc=0.411, P<0.01	ns	ns	ns

LNI, lymph node involvement; ER, oestrogen receptor; PR, progesterone receptor; TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; VDR, vitamin D receptor; cc, coefficient of correlation; ns, not statistically significant. Data presented as correlation coefficient and P-values.

Table V. Correlations among TR, RXR, PPAR and VDR antibodies.

Antigen	TR α 1/2	TR α 1	TR α 2	TR β 1/2	TR β 1	TR β 2	RXR α	PPAR γ	VDR
TR α 1/2	-	cc=0.300 P=0.009	ns	ns	cc=0.247 P=0.032	cc=0.287 P=0.014	cc=0.274 P=0.018	ns	ns
TR α 1	cc=0.300 P=0.009	-	ns	ns	ns	cc=0.291 P=0.013	cc=0.399 P=0.000	ns	ns
TR α 2	ns	ns	-	ns	ns	cc=0.282 P=0.014	cc=0.316 P=0.006	ns	cc=0.433 P=0.000
TR β 1/2	ns	ns	ns	-	ns	ns	ns	ns	ns
TR β 1	cc=0.247 P=0.032	ns	ns	ns	-	cc=0.557 P=0.000	ns	cc=0.270 P=0.017	cc=0.403 P=0.000
TR β 2	cc=0.287 P=0.014	cc=0.291 P=0.013	cc=0.282 P=0.014	ns	cc=0.557 P=0.000	-	ns	cc=0.458 P=0.000	cc=0.370 P=0.001
RXR α	cc=0.274 P=0.018	cc=0.399 P=0.000	cc=0.316 P=0.006	ns	ns	ns	-	ns	ns
PPAR γ	ns	ns	ns	ns	cc=0.270 P=0.017	cc=0.458 P=0.000	ns	-	ns
VDR	ns	ns	cc=0.433 P=0.000	ns	cc=0.403 P=0.000	cc=0.370 P=0.001	ns	ns	-

TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator-activated receptor; VDR, vitamin D receptor; cc, coefficient of correlation; ns, not statistically significant. Data presented as correlation coefficient and P-values.

The rationale for this study was the known significance of immunohistochemical ER/PR expression in breast cancer and the similarity of these receptors with the surface of the other members of the nuclear receptor family. In the latter, ER/PR detection in breast cancer is associated with prognostic relevance (25), and it has long been known that overexpression is treatable with antihormonal therapy (26), regardless of the oestrogen and progesterone blood levels.

Certain authors have focused on thyroid receptors due to an assumed correlation between thyroid dysfunction

and breast cancer (9,27,28). Few studies have reported clear results demonstrating associations, although in these studies, TRs and other histopathological findings were not further differentiated; for example, a negative correlation between the TR receptor level and the axillary involvement of lymph nodes (29). By contrast, Silva *et al* did not find clear correlations between single TR β 1 expression and other histopathological factors (30). The inconsistency between the results of different TRs may be attributable to different distributions of the TRs in the examined tissue (certain

sections had mainly mixed epitopes of TRs, while other sections had mainly single TRs). Taking this into account, as was demonstrated in our study, clear associations between different TRs and histopathological findings support the assumption that the interactions identified may have inherent prognostic relevance.

As with TRs, most of the literature for RXR and PPAR does not refer to *in vivo* but *in vitro* data (31,32). In our study, the expression of RXR, which is known for its antitumour effects, was negatively correlated with differentiation grade (33).

For PPAR γ , an inverse association with tumour size was found (34). In contrast to our previous findings (35), which demonstrated a correlation between PPAR and positive lymph node involvement, discrepant results have also been reported (34). These current conflicting results need to be resolved in larger trials. Hence, drawing clinical conclusions from these findings is considered premature at this time.

In a previous study (36), an immunohistochemical expression of VDR in most of the tumour cells was shown. Nonetheless, data based on the correlation between VDR and ER/PR were inconsistent and contradictory (36-39). Furthermore, the presence of ER/PR and VDR was only partially correlated with other clinical features of tumour stage (36).

We cannot underline the finding of a clear association of VDR and ER/PR but, in contrast to previous findings, our data demonstrated a correlation between VDR, tumour size and lymph node involvement. A single study (40) demonstrated a role for vitamin D and its receptor in breast cancer in humans. As previous data have shown (41,42), an improved outcome was achieved in patients with high VDR-IRS than in patients with low IRS. Taken together, the current findings support the assumption that VDR is a factor with prognostic relevance in breast cancer.

The immunohistochemical association of these receptors supports the knowledge of interactions at the molecular level (43). Hence, these results await confirmation in larger trials. Unfortunately, HER2/neu status was not routinely determined in the cohort investigated at the time of initial diagnosis. Given the high prognostic value of HER2/neu status, it was of significant interest whether this prognosticator also interacts with other receptors. Although selection bias cannot be excluded and the number of patients was small, results may have significance for malignant breast tumour diseases and may be of interest for future innovative therapeutic approaches.

We have demonstrated significant correlations for all the major isoforms of TRs, and furthermore, between RXR, PPAR and VDR. Significantly, and in contrast to TR β 2, TR α 2 demonstrated significant correlations with each of the known independent histopathological markers in breast cancer. It was unusual that, with larger tumour size, higher differentiation grade and axillary lymph node involvement, TR α 2 became negative, but with high ER/PR values, TR increased. This may lead to the assumption that high expression, particularly of TR α 2, is associated with a better prognosis at higher values of ER/PR and therefore protects breast cancer cells from de-differentiation. Furthermore, TR β 2, RXR and VDR were significantly correlated, the latter two of which are known to be of prognostic importance in breast cancer.

Acknowledgements

We thank the patients for providing samples for this study. We acknowledge the excellent technical assistance of M. Rübkeil, S. Hofmann, S. Kunze and C.H. Kuhn.

References

1. Escriva H, Bertrand S and Laudet V: The evolution of the nuclear receptor superfamily. *Essays Biochem* 40: 11-26, 2004.
2. Schröder M, Nayeri S, Kahlen JP, Müller KM and Carlberg C: Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation. *Mol Cell Biol* 15: 1154-1161, 1995.
3. Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JF, Wahli W and Ozato K: Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. *Mol Cell Biol* 4: 2258-2268, 1993.
4. Tanaka T, Danckhe BL, Trifiletti LC, Birnkrant RE, Taylor BJ, Garfield SH, Thorgeirsson U and De Luca LM: Altered localization of retinoid X receptor α coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells. *Mol Cell Biol* 24: 3972-3982, 2004.
5. Tontonoz P, Hu E and Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. *Cell* 79: 1147-1156, 1994.
6. Smallridge RC and Latham KR: Nuclear thyroid hormone receptor in human breast tumours. *Clin Res* 28: 421, 1980.
7. Friedrich M, Axt-Flidner R, Villena-Heinsen C, Tilgen W, Schmidt W and Reichrath J: Analysis of vitamin D-receptor (VDR) and retinoid X-receptor α in breast cancer. *Histochem J* 34: 35-40, 2002.
8. Conde I, Lobo MVT, Zamora J, Pérez J, González FJ, Alba E, Fraile B, Paniagua R and Arenas MI: Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR- α . *BMC Cancer* 8: 174, 2008.
9. Li J, Lin Q, Yoon HG, Huang ZQ, Strahl BD, Allis CD and Wong J: Involvement of histone methylation and phosphorylation in regulation of transcription by thyroid hormone receptor. *Mol Cell Biol* 22: 5688-5697, 2002.
10. Carlstedt-Duke J, Strömstedt PE, Persson B, Cederlund E, Gustafsson JA and Jörnvall H: Identification of hormone-interacting amino acid residues within the steroid-binding domain of the glucocorticoid receptor in relation to other steroid hormone receptors. *J Biol Chem* 263: 6842-6846, 1988.
11. Carlstedt-Duke J: Cellular estrogen activity: implications for pulsed estrogen therapy. *Maturitas* 38 (Suppl 1): S7-S13, 2001.
12. Ling Y, Xu X, Hao J, Ling X, Du X, Liu X and Zhao X: Aberrant methylation of the TRB gene in tissue and plasma of breast cancer patients. *Cancer Genet Cytogenet* 196: 140-145, 2010.
13. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM: Terminal differentiation of human breast cancer through PPAR γ . *Mol Cell* 1: 465-470, 1998.
14. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM and Sporn MB: A new ligand for the peroxisome proliferator activated receptor gamma (PPARgamma), GW7845, inhibits rat mammary carcinogenesis. *Cancer Res* 59: 5671-5673, 1999.
15. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K and Koeffler HP: Novel therapeutic approach: ligands for PPAR γ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. *Breast Cancer Res Treat* 74: 155-165, 2002.
16. Kilgore MW, Tate PL, Rai S, Sengoku E and Price TM: MCF-7 and T47 D human breast cancer cells contain a functional peroxisomal response. *Mol Cell Endocrinol* 129: 229-235, 1997.
17. Zinser GM and Welsh JE: Accelerated mammary gland development during pregnancy and delayed post-lactational involution in vitamin D3 receptor null mice. *Mol Endocrinol* 18: 2208-2223, 2004.
18. Gombart AF, Luong QT and Koeffler HP: Vitamin D compounds: activity against microbes and cancer. *Anticancer Res* 26 (4A): 2531-2542, 2006.

19. Dian D, Janni W, Kuhn C, Mayr D, Karsten U, Mylonas I, Friese K and Jeschke U: Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. *Onkologie* 32: 238-244, 2009.
20. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM and Whelan S (eds): *International Classification of Diseases for Oncology*. 3rd edition. World Health Organization, Geneva, 2000.
21. Elston EW and Ellis IO: Method for grading breast cancer. *J Clin Pathol* 46: 189-190, 1993.
22. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. *Pathologie* 8: 138-140, 1987 (In German).
23. Jeschke U, Bischof A and Speer R: Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodeilin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumours. *Anticancer Res* 25: 1581-1589, 2005.
24. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K and Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. *Anticancer Res* 25: 1719-1723, 2005.
25. Knight WA, Livingston RB, Gregory EJ and McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. *Cancer Res* 37: 4669-4671, 1977.
26. Osborne CK and McGuire WL: The use of steroid hormone receptors in the treatment of human breast cancer: a review. *Bull Cancer* 66: 203-210, 1979.
27. Smyth PPA: The thyroid and breast cancer: a significant association? *Ann Med* 29: 189-191, 1997.
28. Ditsch N, Liebhardt S, von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J and Toth B: Thyroid function in breast cancer patients. *Anticancer Res* 30: 1713-1717, 2010.
29. Lemaire M and Baugnet-Mahieu L: Nuclear thyroid hormone receptors in human cancer tissues. *Anticancer Res* 6: 695-700, 1986.
30. Silva JM, Domínguez G, González-Sancho JM, García JM, Silva J, García-Andrade C, Navarro A, Muñoz A and Bonilla F: Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. *Oncogene* 21: 4307-4316, 2002.
31. Wu K, Zhang Y, Xu XC, Hill J, Celestino J and Kim HT: The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumours in transgenic mice. *Cancer Res* 62: 6376-6380, 2002.
32. Koefler HP: Peroxisome proliferator-activated receptor gamma and cancers. *Clin Cancer Res* 9: 1-9, 2003.
33. Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA and Ando S: Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. *Am J Pathol* 175: 1270-1280, 2009.
34. Suzuki T, Hayashi S, Miki Y, Nakamura Y, Moriya T, Sugawara A, Ishida T, Ohuchi N and Sasano H: Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. *Endocr Relat Cancer* 13: 233-250, 2006.
35. Ditsch N, Vrekoussis T, Lenhard M, Rühl I, Gallwas J, Weissenbacher T, Friese K, Mayr D, Makrigiannakis A and Jeschke U: Retinoid X receptor alpha (RXR α) and peroxisome proliferator-activated receptor gamma (PPAR γ) expression in breast cancer: an immunohistochemical study. *In vivo* 26: 87-92, 2012.
36. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D and Coombes RC: Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. *Cancer Res* 51: 239-244, 1991.
37. Freake HC, Abeyasekera G, Iwasaki J, Marcocci C, MacIntyre I, McClelland RA, Skilton RA, Easton DF and Coombes RC: Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. *Cancer Res* 44: 1677-1681, 1984.
38. Mason BH, Holdaway IM, Mullins PR, Yee LH and Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. *Cancer Res* 43: 2985-2990, 1983.
39. Howat JM, Harris M, Swindell R and Barnes DM: The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. *Br J Cancer* 51: 263-270, 1985.
40. McCullough ML, Bostick RM and Mayo TL: Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. *Annu Rev Nutr* 29: 111-132, 2009.
41. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW and Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. *Cancer Res* 47: 6793-6799, 1987.
42. Ditsch N, Toth B, Mayr D, Lenhard M, Gallwas J, Weissenbacher T, Dannecker C, Friese K and Jeschke U: The association between vitamin D receptor and prolonged overall survival in breast cancer. *J Histochem Cytochem* 60: 121-129, 2012.
43. Sanchez-Martinez R, Zambrano A, Castillo AI and Aranda A: Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. *Mol Cell Biol* 28: 3817-3829, 2007.